• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aclarion Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8/16/24 4:56:50 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    Aclarion, Inc. 8-K
    false 0001635077 0001635077 2024-08-14 2024-08-14 0001635077 ACON:CommonStockParValue0.00001PerShareMember 2024-08-14 2024-08-14 0001635077 ACON:WarrantsEachExercisableForOneShareOfCommonStockMember 2024-08-14 2024-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 16, 2024 (August 14, 2024)

     

    Aclarion, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 001-41358 47-3324725
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

     

    8181 Arista Place, Suite 100  
    Broomfield, Colorado 80021
    (Address of Principal Executive Offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (833) 275-2266

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

      Trading  
    Title of each class Symbol(s) Name of each exchange on which registered
    Common Stock ACON Nasdaq Stock Market
    Common Stock Warrants ACONW Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Background

     

    As previously disclosed, on September 1, 2023, Aclarion, Inc. (the “Company”, “we” and “us”) closed a financing for $862,500 of unsecured non-convertible notes due September 1, 2024.

     

    Exchange Agreement

     

    On August 14, 2024, the Company entered into an exchange agreement (the “Exchange Agreement”) with the note holders accredited investors to exchange approximately $930,000 of principal and accrued interest on the notes for 930 shares of newly issued Series B convertible preferred stock (“Series B Preferred Stock”) at a purchase price  of $1,000 per share of Series B Preferred Stock. The Series B Preferred Stock is convertible into Common Stock at an initial conversion price (“Conversion Price”) of $0.234 per share of Common Stock.

     

    Terms of the Series B Preferred Stock

     

    The Company has filed a Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock (“Certificate of Designations”) with the Secretary of State of the State of Delaware.

     

    Rank

     

    The Certificate of Designations provides that the Series B Preferred Stock ranks senior to the Common Stock with respect to dividends and rights upon liquidation.

     

    Voting Rights

     

    Except as otherwise required by law (or with respect to approval of certain actions), the Series B Preferred Stock will not have voting rights.

     

    Dividends

     

    Holders of the Series B Preferred Stock will be entitled to dividends in the amount of 10% per annum, payable quarterly.

     

    The Company has the option to pay dividends on the Series B Preferred Stock in additional shares of Common Stock, provided that no equity conditions failure (as defined in the Certificate of Designations) then exists. If the Company elects to pay in the form of Common Stock, the number of dividend shares to be issued shall be calculated by using a “Dividend Conversion Price” equal to the lower of (i) the then applicable Series B Conversion Price as in effect on the applicable dividend date, or (ii) 90% of the lowest volume weighted average price of the Common Stock during the five (5) consecutive trading day period ending and including the trading day immediately preceding the applicable dividend date.

     

    The Company also has the option to cumulate or “capitalize” the dividends, in which case the accrued dividend amount shall be added to the stated value of each share of Series B Preferred Stock.

     

     

     

     2 

     

     

    Conversion Rights; Anti-Dilution Adjustments

     

    The stated value of each share of Series B Preferred Stock (including all the unpaid dividends and other amounts payable on the Series B Preferred Stock) will be convertible into Common Stock at an initial fixed Conversion Price of $0.234 per share of Common Stock. The Series B Preferred Stock may be converted into shares of Common Stock at any time at the option of the holder. The Series B Preferred Stock may also be converted into shares of Common Stock at the option of the Company if the closing price of the Common Stock equals at least 300% of the Conversion Price for 20 consecutive trading days, provided that no equity conditions failure (as defined in the Certificate of Designations) then exists.

     

    The Conversion Price of the Series B Preferred Stock is subject to certain anti-dilution adjustments, including in the event of any stock splits or combinations, certain dividends and distributions, reclassification, exchange or substitution of the Company’s Common Stock or in the event that the Company grants, issues or sells (or enters into any agreement to grant, issue or sell), or is deemed to have granted, issued or sold, any shares of Common Stock for a consideration per share (the “New Issuance Price”) less than a price equal to the Conversion Price in effect immediately prior to such granting, issuance or sale or deemed granting, issuance or sale (the foregoing a “Dilutive Issuance”). Immediately after such Dilutive Issuance, the Conversion Price then in effect shall be reduced to an amount equal to the New Issuance Price.

     

    Limitations on Conversion

     

    Exchange Cap Limitation. The holders will not be able to receive shares upon conversion of the Series B Preferred Stock, unless prior stockholder approval is obtained, if (i) the number of shares to be issued would exceed 20% of the Company’s outstanding number of shares at a discount to the applicable Nasdaq Minimum Price or (ii) the number of shares to be issued to any holder would result in in a Change of Control within the meaning of Nasdaq Rule 5635(b).

     

    Beneficial Ownership Limitation. The Company shall not effect the conversion of any of the Series B Preferred Stock held by a holder, and such holder shall not have the right to convert any of the Series B Preferred Stock to the extent that after giving effect to such conversion or exercise, such holder would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such conversion or exercise (which percentage is subject to increase to 9.99% or decrease, at the option of such holder, except that any raise will only be effective upon 61-days’ prior notice to us).

     

    Defaults; Triggering Events; Alternate Conversion Price

     

    The Certificate of Designations contains customary events of default, or “Triggering Events”, including, among others, (i) certain events of bankruptcy, insolvency or reorganization; (ii) failure to comply with the listing rules of Nasdaq; (iii) certain breaches of the transaction agreements related to this financing; and (iv) any of the shares of the Series B Preferred Stock remaining outstanding on or after August 14, 2026.

     

    Upon the occurrence of a Triggering Event, (i) the dividend rate on the Series B Preferred Stock will increase to 18%, and (ii) the Conversion Price then in effect will be adjusted to an “Alternate Conversion Price” equal to the lowest of (i) the applicable Conversion Price as then in effect, and (ii) the greater of (x) the “Floor Price” of $0.0468 and (y) 80% of the lowest volume weighted average price of the Common Stock during the five (5) consecutive trading day period immediately preceding the delivery or deemed delivery of the applicable conversion notice.

     

    Redemption

     

    At any time, the Company shall have the right to redeem all, but not less than all, of the Series B Preferred Shares then outstanding in cash at a price equal to at a 25% premium to the greater of (i) the applicable redemption amount and (ii) the equity value of the shares of our Common Stock underlying the Series B Preferred Shares included in the applicable redemption amount. The equity value of our Common Stock is calculated is calculated using the greatest closing sale price of our Common Stock during the period commencing on the date immediately preceding our notice of such redemption and ending the we make the entire payment required.

     

     

     

     3 

     

     

    Liquidation Value

     

    Upon our liquidation, dissolution or winding up, holders of Series B Preferred Stock shall be entitled to receive in cash out of the assets of the Company, before any amount shall be paid to the holders of any of shares of Common Stock, an amount per Series B Preferred Share equal to the greater of (A) 125% of the applicable liquidation value and (B) the amount per share such holder would receive if such holder converted such share of Series B Preferred Stock into Common Stock immediately prior to the date of such payment.

     

    ******

     

    The foregoing summaries of the Exchange Agreement and the Certificate of Designations do not purport to be complete and are subject to, and qualified in their entirety by, such documents attached as exhibits to this Current Report on Form 8-K, which are incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    The securities described above have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act afforded by Section 3(a)(9) thereof.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit

    Number

      Description
         
    3.1  

    Series B Convertible Preferred Stock Certificate of Designations dated August 14, 2024

         
    10.1   Form of Exchange Agreement dated August 14, 2024
         
    104   Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

     

     

     

     

     

     

     

     4 

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ACLARION, INC.
         
    August 14, 2024 By:/s/ John Lorbiecki
      Name: John Lorbiecki
      Title: Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     5 

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclarion Publishes 2026 Shareholder Letter from the Chairman

    Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initia

    2/5/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

    Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedureSupports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Heal

    2/3/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

    BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially strengthens Aclarion's balance sheet, preserves capital structure integrity, and significantly extends the Company's operating runway well past targeted near and medium-term catalysts while enhancing strategic flexibi

    1/13/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 4 filed by CFO Gould Gregory A

    4 - Aclarion, Inc. (0001635077) (Issuer)

    9/3/25 5:10:03 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Gould Gregory A

    3 - Aclarion, Inc. (0001635077) (Issuer)

    9/3/25 5:05:26 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    SEC Filings

    View All

    Aclarion Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aclarion, Inc. (0001635077) (Filer)

    1/13/26 9:00:25 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Aclarion, Inc. (0001635077) (Filer)

    1/9/26 9:03:07 AM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Aclarion Inc.

    424B5 - Aclarion, Inc. (0001635077) (Filer)

    1/9/26 9:00:15 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

    Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announc

    11/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Greg Gould as Chief Financial Officer

    HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity BROOMFIELD, Colo., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced the appointment of Greg Gould as Chief Financial Officer (CFO), effective immediately. Greg brings mor

    9/3/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    11/13/24 3:06:29 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Aclarion Inc.

    SC 13G - Aclarion, Inc. (0001635077) (Subject)

    9/5/24 4:19:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    3/29/24 5:00:57 PM ET
    $ACON
    Medical Specialities
    Health Care